Table 4.

Association Between Characteristics of Heart and Lung Transplant Recipients and Development of an Antibody Response to Each Dose of SARS-CoV-2 Messenger RNA Vaccine

	Dose 1			Dose 2
	Univariate analysis	Multivariate analysis		Univariate analysis	Multivariate analysis
Recipient characteristics	p value	aIRRa	p value	p value	aIRRa	p value
		(95% CI)			(95% CI)
Ageb	.054	0.61 (0.41-0.92)	.02	.2	0.93 (0.81-1.08)	.4
Female sex	.7	0.74 (0.38-1.43)	.4	.054	0.80 (0.64-1.00)	.051
Type of organ transplantc	.3	1.19 (0.59-2.42)	.6	<.001	1.55 (1.18-2.03)	.001
Time since transplantd	.2	1.28 (0.95-1.72)	.11	<.001	1.22 (1.10-1.35)	<.001
Anti-metabolite maintenance immunosuppressione	<.01	0.43 (0.22-0.85)	.02	<.001	0.71 (0.58-0.88)	<.01
Vaccine typef	.09	1.66 (0.83-3.30)	.15	.4	1.10 (0.89-1.37)	.2

aIRR, adjusted incident rate ratio. n = 237.

^aModel adjusted for age, sex, transplant type, time since transplant, anti-metabolite maintenance immunosuppression, and vaccine type. Comparison of mRNA-1273 and BNT16b2 was further adjusted for number of days between vaccination and antibody testing.

^bAge treated as continuous.

^cComparison of heart (reference) vs lung transplant recipients.

^dComparison of 6 or more years since transplant vs less than 6 years since transplant.

^eAntimetabolite maintenance immunosuppressive regimens included mycophenolate mofetil, mycophenolic acid, and azathioprine.

^fComparison of mRNA-1273 (reference) BNT162b2 vaccine.